[Thrombin generation assay in autoimmune disease]

Rev Med Interne. 2021 Dec;42(12):862-868. doi: 10.1016/j.revmed.2021.06.006. Epub 2021 Jun 24.
[Article in French]

Abstract

Thrombin generation assay (TGA) is a useful tool to evaluate the initiation, propagation and inhibition of coagulation. TGA is a global test that is used to assess hemorrhagic risk in hemophilia patients, but it can also be used to study hypercoagulable states. The interest of TGA is to screen for cardiovascular risk, which is regularly associated with autoimmune disease (AID) such as antiphospholipid syndrome. Indeed, TGA has been used to evaluate hypercoagulability in patients with antiphospholipid syndrome treated with rivaroxaban versus warfarin. In other AIDs without thrombotic events, TGA measurement is elevated, mainly in rheumatoid arthritis (RA), systemic lupus erythematosus and Behçet's disease. These findings in RA are correlated with the inflammatory activity of the disease. In systemic lupus erythematosus and Behçet's disease, TGA appears to reflect disease activity. In conclusion, TGA remains relatively under used in the clinical evaluation of AID, but it could play a greater role in the evaluation of certain potentially thrombogenic treatments in AID. Finally, TGA helps measuring AID activity, due to the clearlink between coagulation and inflammation, despite some limitations of interpretation mainly due to a lack of standardization.

Keywords: Auto immune disease; Hypercoagulability; Hypercoagulabilité; Maladie auto-immune; Test de génération de thrombine; Thrombin generation assay.

MeSH terms

  • Antiphospholipid Syndrome* / diagnosis
  • Autoimmune Diseases* / diagnosis
  • Autoimmune Diseases* / epidemiology
  • Blood Coagulation
  • Humans
  • Rivaroxaban
  • Thrombin

Substances

  • Rivaroxaban
  • Thrombin